Nicholas Shelley, NP
Nurse Practitioner · Fort Myers, FLNPI 1215410220
Payments from drug & device makers
Across 163 payments — averaging $19.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$648
- AbbVie$308
- Dexcom, Inc.$233
- Antares Pharma, Inc.$232
- Boston Scientific$157
- Lilly USA, LLC$136
- plus $1K from 27 others
What the payments were for
- Food & beverage$3,111100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 44 | $648 |
| AbbVie | 14 | $308 |
| Dexcom, Inc. | 14 | $233 |
| Antares Pharma, Inc. | 12 | $232 |
| Boston Scientific | 2 | $157 |
| Lilly USA, LLC | 7 | $136 |
| AstraZeneca | 8 | $128 |
| Tandem Diabetes Care, Inc. | 4 | $128 |
| Xeris Pharmaceuticals, Inc. | 6 | $117 |
| Lifescan, Inc. | 6 | $101 |
| Corcept Therapeutics | 5 | $99 |
| Kyowa Kirin, Inc. | 4 | $94 |
| Amgen | 4 | $89 |
| Amneal Pharmaceuticals LLC | 4 | $79 |
| Halozyme Inc | 3 | $57 |
| Esperion Therapeutics, Inc. | 3 | $54 |
| Abbott | 2 | $50 |
| Embecta Corp. | 2 | $41 |
| Amarin Pharma, Inc. | 2 | $39 |
| Sanofi-aventis U.S. LLC | 2 | $38 |
| GRT US Holding, Inc. | 2 | $35 |
| Radius Health, Inc. | 2 | $33 |
| Medtronic | 1 | $30 |
| Averitas Pharma Inc. | 1 | $27 |
| Ultragenyx Pharmaceutical Inc. | 1 | $25 |
| Merck | 1 | $24 |
| Stimwave Technologies Incorporated | 1 | $22 |
| Mannkind Corporation | 1 | $21 |
| Recordati_rare_diseases_inc. | 1 | $20 |
| Almatica Pharma LLC | 1 | $17 |
| Insulet Corporation | 1 | $17 |
| Tolmar, Inc. | 1 | $15 |
| Vistapharm, Inc. | 1 | $11 |
How this compares
$3,122 in reported general payments places this provider in the 85th percentile of 8,290 nurse practitioner providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 170 | $226,456 |
| JardianceEmpagliflozin | 143 | $222,262 |
| OzempicSemaglutide | 86 | $156,386 |
| JanumetSitagliptin Phos/Metformin Hcl | 125 | $146,144 |
| FarxigaDapagliflozin Propanediol | 78 | $104,768 |
| Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro | 126 | $83,920 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 150 | $74,888 |
| TrulicityDulaglutide | 44 | $70,860 |
| MounjaroTirzepatide | 22 | $35,483 |
| TradjentaLinagliptin | 26 | $31,383 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 102 | $29,964 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 19 | $29,305 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $27,966 |
| Novolog FlexpenInsulin Aspart | 47 | $26,983 |
| Humalog Kwikpen U-100Insulin Lispro | 41 | $26,810 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet, Janumet Xr | $24 | $401,905314 claims |
| Boehringer IngelheimJardiance, Tradjenta, Jentadueto | $648 | $270,520183 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $136 | $106,34366 claims |
| AstraZenecaFarxiga | $128 | $104,76878 claims |
| AbbVieSynthroid | $308 | $8,989131 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $79 | $5,581743 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,290 nurse practitioner providers in Florida.
Other nurse practitioner in Fort Myers
- Laura TaylorFort Myers$27K
- Jolanta BaginskiClearwater$494K
- Adissa PerezWinter Park$370K
- April WessonTampa$342K
- Margarita FernandezMiami$311K
- Stephanie SimmermanNaples$283K
- Claudette WalkerPonte Vedra Beach$271K
- Lisa NodzonTampa$246K
- Ashima BahlTampa$226K
- Maya BloombergMiami$202K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.